Recent Activity

Loading...

ANVS

Annovis Bio Inc · NYSE

Performance

+37.81%

1W

-17.56%

1M

-20.33%

3M

+43.03%

6M

-55.56%

YTD

-38.85%

1Y

Profile

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which is in Phase 3 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405 for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.

Technical Analysis of ANVS 2024-05-10

Overview:

In analyzing the technical indicators for ANVS over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement in the coming days.

Trend Analysis:

  • Moving Averages (MA): The 5-day MA has been declining, indicating a short-term bearis...
See more ...

Recent News & Updates